secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibrx Biosciences, Inc. (INBX)
CIK:        0002007919
Form:       8-K
Filed at:   2025-12-16T23:59:59+00:00
Accession:  0002007919-25-000097
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibrx provides INBRX-106 and ozekibart trial updates; Ewing sarcoma FDA meeting planned for H2 2026
--------------------------------------------------------------------------------

- INBRX-106 HNSCC Phase 2/3: 46 of 60 patients enrolled; completion expected Q1 2026.
- NSCLC Phase 1/2 trial completed enrollment of 34 patients in Nov 2025; data immature.
- Ozekibart colorectal cancer expansion cohort enrolled 44 patients; PFS data mature Q2 2026.
- Ewing sarcoma trial enrollment expected Q2 2026; FDA meeting for accelerated approval planned H2 2026 if trends continue.
- No efficacy data released; management cautions datasets lack maturity for conclusions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2007919/000200791925000097/0002007919-25-000097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2007919/000200791925000097/inhibrx-20251216.htm
  HTML page:      https://secwatch.observer/filing/0002007919-25-000097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer